Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
AnGes MG Resumes Development of NF-κB Decoy Oligo Ointment Formulation for Atomic Dermatitis
AnGes MG announced on August 25 that it will initiate a PIII clinical study for an ointment formulation of its atopic dermatitis treatment NF-κB decoy oligo in Japan. The development of the ointment has been suspended because AnGes MG and…
To read the full story
BUSINESS
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
- Novartis, JSH Begin Project to Address Regional Gaps in Hematology Care
April 14, 2026
- Nxera to Receive US$22.5 Million Milestone as Schizophrenia Drug Enters PII
April 14, 2026
- Itochu Unit to Import Sodium, Potassium Chloride from Germany
April 14, 2026
- JCR Launches PIII Dose Comparison Study of Growject in Japan
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…